Oricell Therapeutics

Chinese clinical-stage biotech developing next-generation CAR-T cell therapies for solid tumors. Lead asset Ori-C101 targets hepatocellular carcinoma (liver cancer), aiming to become the first globally-approved CAR-T for the disease. Pipeline focused on overcoming the historical limitations of CAR-T in solid tumors.